Photo Release -- AIBioTech Executive VP to Present Largest Pharmacogenomic Study to Date at IONWorld2013

Thomas Reynolds - In Office
AIBioTech Logo

RICHMOND, Va., Oct. 15, 2013 (GLOBE NEWSWIRE) -- AIBioTech Co-Founder and Executive Vice President Thomas Reynolds will present the results of a novel multiplex pharmacogenomics panel and accompanying data at the IONWorld2013 conference October 21, in Boston, Massachusetts.

AIBioTech Executive Vice President will present CYP enzyme genetic data collected from more than 10,000 patient samples at this month's IONWorld conference.

A photo accompanying this release is available at

Reynolds will present AIBioTech's process for developing its multiplex Personalized Medicine Panel as well as genotyping frequencies on all genes in AIBioTech's panel for more than ten thousand de-identified clinical specimens. His presentation will also compare AIBioTech's large pool of clinical data to published genotype frequencies from smaller studies in four different ethnic populations: African-American, Caucasian, Hispanic, and Asian.

"The data generated from this study will provide new insights into the ethnic frequency of CYP enzyme mutations that affect drug dosing and management," said Reynolds.

AIBioTech's Personalized Medicine Panel utilizes Next Generation sequencing technology on the Ion Torrent Personal Genome Machine™ to analyze ten genetic markers associated with the Cytochrome P450 (CYP) enzymes that metabolize many commonly prescribed drugs and cardiac risk factors Factor II (prothrombin), Factor V Leiden, and MTHFR.

The panel categorizes patients into one of four metabolizer categories for each of the enzyme markers and provides actionable information for physicians regarding dosing and possible negative drug interactions. AIBioTech has processed more than twenty thousand patient samples on this platform to date, a unique milestone for any laboratory utilizing the ION Torrent technology.

About AIBioTech® (American International Biotechnology Services, LLC)

AIBioTech is a unique combination of diagnostic laboratory and comprehensive contract research organization. Based on over 20 years of experience with DNA sequencing, assay development and practical research applications, AIBioTech provides clinical testing services and research and development services to physicians and life science investigators in clinical practices; biotechnology and pharmaceutical companies; academic institutions and in several different government agencies For more information about its capabilities and services visit the company website at

The photo is also available via AP PhotoExpress.

CONTACT: Andrea Spivey, Marketing Manager 804.521.7378

Source: AIBioTech